2型糖尿病患者新型脂肪因子血清内脏脂肪素和内脏脂肪特异性丝氨酸蛋白酶抑制因子的表达水平与左心室肥厚的关系

doi:10.3969/j.issn.1006-7795.2022.05.016

摘要/Abstract

摘要： 目的研究2型糖尿病(type 2 diabetes mellitus,T2DM)患者新型脂肪因子血清内脏脂肪素(visfatin)、内脏脂肪特异性丝氨酸蛋白酶抑制因子(vaspin)的表达水平与左心室肥厚(left ventricular hypertrophy,LVH)的关系。探讨影响T2DM患者发生LVH的相关因素。方法入选93例明确诊断为T2DM患者,行超声心动图检查评估心脏结构功能,并计算左室心肌质量指数(left ventricular mass index,LVMI)。根据 LVMI 将患者分为 T2DM合并LVH 组(病例组,n=45)与T2DM不合并 LVH 组(对照组,n=48),收集患者一般情况,检测生物化学指标、血清vaspin和visfatin等指标。分析vaspin和visfatin在T2DM中表达情况与 LVH 的相关性。结果相较于对照组,病例组的visfatin和vaspin浓度升高[(4.57±2.74)ng/mL vs (3.35±2.05)ng/mL,(417.40±230.71)pg/mL vs (328.07±218.99)pg/mL,P<0.05]。Logistic多因素回归分析显示,visfatin、冠状动脉粥样硬化性心脏病、高密度脂蛋白胆固醇(high density lipoprotein-cholesterol,HDL-C)是T2DM合并 LVH 的独立预测因素(P<0.05)。在对visfatin与糖脂代谢相关因素分析中发现,T2DM人群中visfatin浓度与HDL-C呈负相关(P<0.05)。结论在T2DM患者中,随着 LVMI的增加,血清visfatin浓度增加。Visfatin可能参与了T2DM发生LVH的病理过程,并与糖脂代谢紊乱相关。Visfatin可能是T2DM患者发生 LVH 的预测因素。

关键词: 2型糖尿病, 内脏脂肪素, 内脏脂肪特异性丝氨酸蛋白酶抑制因子, 左心室肥厚

Abstract: Objective To explore the relationship between the expression of new adipokines in serum such as visfatin and vaspin,and left ventricular hypertrophy (LVH) in patients with type 2 diabetes mellitus (T2DM). We studied the related factors affecting LVH in T2DM.Methods Totally 93 patients with T2DM were enrolled, all patients were tested for biochemical indicators and blood routine indicators, echocardiography was done, the left ventricular myocardial mass index (LVMI) was calculated. According to LVMI, patients were divided into T2DM with LVH group (case group, n=45) versus T2DM without LVH group (control group, n=48), Logistic regression was used to analyze the correlation between visfatin, vaspin and LVH in T2DM patients. Results Compared with the control group, the concentrations of visfatin and vaspin in the case group were increased [(4.57±2.74)ng/mL vs (3.35±2.05)ng/mL,(417.40±230.71)pg/mL vs (328.07±218.99)pg/mL], and the difference was statistically significant (P< 0.05). The results of Logistic multivariate regression analysis showed that visfatin, coronary heart disease, and high density lipoprotein-cholesterol(HDL-C)were independent predictors of T2DM combined with LVH. Further analysis of the factors related to visfatin and glucose and lipid metabolism showed that the level of visfatin was negatively correlated with HDL-C in T2DM population (P<0.05). Conclusion Serum visfatin concentrations were increased with LVMI in T2DM and associated with glycolipid metabolism disorder. Visfatin may be involved in the pathological process of developing LVH in T2DM.It may be a predictive factor for the development of LVH in patients with diabetes.

Key words: type 2 diabetes, visfatin, vaspin, left ventricular hypertrophy

中图分类号:

R541.8

马艺欣, 张仲迎, 佀思聪, 罗鸿宇, 赵欢, 杨伟. 2型糖尿病患者新型脂肪因子血清内脏脂肪素和内脏脂肪特异性丝氨酸蛋白酶抑制因子的表达水平与左心室肥厚的关系[J]. 首都医科大学学报, 2022, 43(5): 767-773.

Ma Yixin, Zhang Zhongying, Si Sicong, Luo Hongyu, Zhao Huan, Yang Wei. The relationship between the new adipokines visfatin and vaspin expression in patients with type 2 diabetes mellitus and left ventricular hypertrophy[J]. Journal of Capital Medical University, 2022, 43(5): 767-773.

参考文献

[1] Morson B. President's address. The polyp-cancer sequence in the large bowel[J]. Proc R Soc Med, 1974, 67(6 Pt 1): 451-457.
[2] Fearon E R, Vogelstein B. A genetic model for colorectal tumorigenesis[J]. Cell, 1990, 61(5): 759-767.
[3] Shaukat A, Kaltenbach T, Dominitz J A, et al. Endoscopic recognition and management strategies for malignant colorectal polyps: recommendations of the US Multi-Society task force on colorectal cancer[J]. Gastroenterology, 2020, 159(5): 1916-1934.e2.
[4] Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?[J]. Lancet, 2001, 357(9255): 539-545.
[5] Fabris L, Sato K, Alpini G, et al. The tumor microenvironment in cholangiocarcinoma progression[J]. Hepatology, 2021, 73 Suppl 1(Suppl 1): 75-85.
[6] Marques P, Barry S, Carlsen E, et al. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours[J]. Acta Neuropathol Commun, 2019, 7(1): 172.
[7] Bugada D, Allegri M, Lavand'homme P, et al. Inflammation-based scores: a new method for patient-targeted strategies and improved perioperative outcome in cancer patients[J]. Biomed Res Int, 2014, 2014: 142425.
[8] Balkwill F R, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities[J]. Semin Cancer Biol, 2012, 22(1): 33-40.
[9] Ahmad J, Grimes N, Farid S, et al. Inflammatory response related scoring systems in assessing the prognosis of patients with pancreatic ductal adenocarcinoma: a systematic review[J]. Hepatobiliary Pancreat Dis Int, 2014, 13(5): 474-481.
[10] Yang T, Mao P, Chen X H, et al. Inflammatory biomarkers in prognostic analysis for patients with glioma and the establishment of a nomogram[J]. Oncol Lett, 2019, 17(2): 2516-2522.
[11] McMillan D C. Systemic inflammation, nutritional status and survival in patients with cancer[J]. Curr Opin Clin Nutr Metab Care, 2009, 12(3): 223-226.
[12] Chang X F, Zhang F, Liu T S, et al. Neutrophil-to-lymphocyte ratio as an Independent predictor for survival in patients with localized clear cell renal cell carcinoma after radiofrequency ablation: a propensity score matching analysis[J]. Int Urol Nephrol, 2017, 49(6): 967-974.
[13] Huang H P, Liu Q, Zhu L X, et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer[J]. Sci Rep, 2019, 9(1): 3284.
[14] Terasaki F, Sugiura T, Okamura Y, et al. Systemic immune-inflammation index as a prognostic marker for distal cholangiocarcinoma[J]. Surg Today, 2021, 51(10): 1602-1609.
[15] Naszai M, Kurjan A, Maughan T S. The prognostic utility of pre-treatment neutrophil-to-lymphocyte-ratio (NLR) in colorectal cancer: a systematic review and meta-analysis[J]. Cancer Med, 2021, 10(17): 5983-5997.
[16] Jia W Q, Yuan L, Ni H Y, et al. Prognostic value of platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte ratio, and lymphocyte-to-white blood cell ratio in colorectal cancer patients who received neoadjuvant chemotherapy[J]. Technol Cancer Res Treat, 2021, 20: 15330338211034291.
[17] Dong M L, Shi Y G, Yang J, et al. Prognostic and clinicopathological significance of systemic immune-inflammation index in colorectal cancer: a meta-analysis[J]. Ther Adv Med Oncol, 2020, 12: 1758835920937425.
[18] Zhou W W, Chu Y P, An G Y. Significant difference of neutrophil-lymphocyte ratio between colorectal cancer, adenomatous polyp and healthy People[J]. Eur Rev Med Pharmacol Sci, 2017, 21(23): 5386-5391.
[19] Roxburgh C S D, McMillan D C. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer[J]. Future Oncol, 2010, 6(1): 149-163.
[20] De Larco J E, Wuertz B R K, Furcht L T. The potential role of neutrophils in promoting the metastatic phenotype of tumors releasing interleukin-8[J]. Clin Cancer Res, 2004, 10(15): 4895-4900.
[21] Halazun K J, Hardy M A, Rana A A, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma[J]. Ann Surg, 2009, 250(1): 141-151.
[22] Kusumanto Y H, Dam W A, Hospers G A P, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor[J]. Angiogenesis, 2003, 6(4): 283-287.
[23] Houghton A M, Rzymkiewicz D M, Ji H B, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth[J]. Nat Med, 2010, 16(2): 219-223.
[24] Li N L. Platelets in cancer metastasis: to help the “villain” to do evil[J]. Int J Cancer, 2016, 138(9): 2078-2087.
[25] Stegner D, Dütting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis[J]. Thromb Res, 2014, 133 Suppl 2: S149-S157.
[26] Franco A T, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer[J]. Blood, 2015, 126(5): 582-588.
[27] Calman K C. Tumour immunology and the gut[J]. Gut, 1975, 16(6): 490-499.
[28] Waldner M, Schimanski C C, Neurath M F. Colon cancer and the immune system: the role of tumor invading T cells[J]. World J Gastroenterol, 2006, 12(45): 7233-7238.
[29] Morson B C, Whiteway J E, Jones E A, et al. Histopathology and prognosis of malignant colorectal polyps treated by endoscopic polypectomy[J]. Gut, 1984, 25(5): 437-444.
[30] Uçmak F, Tuncel E T. Relationship between lesions in adenomatous polyp-dysplasia-colorectal cancer sequence and neutrophil-to-lymphocyte ratio[J]. Med Sci Monit, 2016, 22: 4536-4541.
[31] Sumimoto K, Tanaka S, Shigita K, et al. Clinical impact and characteristics of the narrow-band imaging magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team[J]. Gastrointest Endosc, 2017, 85(4): 816-821.